Fluconazole and Ibuprofen Combination: A Potential Treatment for Mucosal Candidiasis
Author(s) -
Tahere Shamoushaki,
Leila Fozouni
Publication year - 2020
Publication title -
medical laboratory journal
Language(s) - English
Resource type - Journals
ISSN - 2538-4449
DOI - 10.29252/mlj.14.5.25
Subject(s) - fluconazole , microbiology and biotechnology , candida glabrata , candida parapsilosis , candida albicans , candida tropicalis , broth microdilution , drug resistance , corpus albicans , minimum inhibitory concentration , ibuprofen , biology , medicine , pharmacology , antifungal , antibiotics
Background and objectives: The incidence of drug-resistant candidiasis has increased dramatically. This study aimed to evaluate antifungal effects of fluconazole alone and in combination with ibuprofen on isolates from patients with mucosal candidiasis. Methods: Candida species isolates from 142 patients with suspected mucosal (oral and vaginal) candidiasis were identified by culture on CHROMagar Candida medium and carbohydrate assimilation test using the API 20CAUX kit. Minimum inhibitory concentration (MIC) of fluconazole alone and in combination with ibuprofen was determined by the broth microdilution method. Results: Among isolates, 43.7% were identified as Candida species (Candida albicans, Candida glabrata, Candidia parapsilosis, Candida tropicalis, Candida guilliermondii and Candida kefyr). The highest rate of fluconazole resistance was observed among C. albicans (50%) isolates. MIC90 of ibuprofenfluconazole combination against C. albicans isolates was 32 μg/mL, which was 8-fold less than that of fluconazole alone (MIC90=256 μg/mL) (P<0.01). Moreover, the MIC90 of fluconazole-ibuprofen combination against C. parapsilosis isolates was 4-fold less than that of fluconazole alone. Conclusion: Our results revealed partial fluconazole resistance among Candida isolates from patients with mucosal candidiasis. However, the resistance rate decreased 2.5 fold following treatment with the ibuprofen-fluconazole combination. Therefore, it is recommended to further investigate the therapeutic potential of this drug combination for treatment of fungal infections, such as candidiasis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom